Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387360641> ?p ?o ?g. }
Showing items 1 to 73 of
73
with 100 items per page.
- W4387360641 abstract "Abstract Disclosure: S. Kaul: None. A. Gupta: None. Introduction: PCKS9 inhibitors, such as evolocumab, have been shown to lower triglyceride levels by approximately 10-20% (1). However, there have not been any reports of PCSK9 inhibitors lowering triglyceride levels by more than 100%. Clinical Case: A 35-year-old white man presented with hypertriglyceridemia for more than eight years. Past medical history was significant for recurrent pancreatitis and diabetes mellitus type 2 with recent HbA1c of 7.6% (normal range <5.7%) on metformin 1 gram BID and insulin glargine 15 units daily. He had multiple hospitalizations for pancreatitis requiring insulin drip. His triglycerides remained elevated on fenofibrate, atorvastatin, and icosapent ethyl despite alcohol avoidance and changes in diet with progressive elevation to 5000 mg/dL (normal range 0-150 mg/dL) requiring four sessions of plasmapheresis and hospitalization requiring intravenous insulin drip. His family history also included hypertriglyceridemia in his mother. He was started on evolocumab 140 mg subcutaneously every 2 weeks and noted to have drastic improvement of triglycerides down to a normal level of 138 mg/dL. On recent labs, his triglyceride level was noted to be 921 mg/dL with HbA1c at 8.0%. He did admit non-compliance to diet but did not require any more hospitalizations for pancreatitis since starting evolocumab. Conclusions: This is the first reported case of an unexplored potential of evolocumab in patients with severe hypertriglyceridemia. Reference: (1) Warden BA, Fazio S, Shapiro MD. The PCSK9 revolution: Current status, controversies, and future directions. Trends Cardiovasc Med. 2020;30(3):179-185. doi:10.1016/j.tcm.2019.05.007 Presentation: Friday, June 16, 2023" @default.
- W4387360641 created "2023-10-06" @default.
- W4387360641 creator A5002872509 @default.
- W4387360641 creator A5005301450 @default.
- W4387360641 date "2023-10-01" @default.
- W4387360641 modified "2023-10-06" @default.
- W4387360641 title "FRI101 Marked Reduction In Severe Resistant Hypertriglyceridemia On PCSK9 Inhibitor" @default.
- W4387360641 doi "https://doi.org/10.1210/jendso/bvad114.615" @default.
- W4387360641 hasPublicationYear "2023" @default.
- W4387360641 type Work @default.
- W4387360641 citedByCount "0" @default.
- W4387360641 crossrefType "journal-article" @default.
- W4387360641 hasAuthorship W4387360641A5002872509 @default.
- W4387360641 hasAuthorship W4387360641A5005301450 @default.
- W4387360641 hasBestOaLocation W43873606411 @default.
- W4387360641 hasConcept C126322002 @default.
- W4387360641 hasConcept C134018914 @default.
- W4387360641 hasConcept C2775967933 @default.
- W4387360641 hasConcept C2776670229 @default.
- W4387360641 hasConcept C2776919658 @default.
- W4387360641 hasConcept C2777180221 @default.
- W4387360641 hasConcept C2777482532 @default.
- W4387360641 hasConcept C2778096610 @default.
- W4387360641 hasConcept C2778110834 @default.
- W4387360641 hasConcept C2778114629 @default.
- W4387360641 hasConcept C2778163477 @default.
- W4387360641 hasConcept C2778913445 @default.
- W4387360641 hasConcept C2779091943 @default.
- W4387360641 hasConcept C2780323712 @default.
- W4387360641 hasConcept C2780745583 @default.
- W4387360641 hasConcept C2910068830 @default.
- W4387360641 hasConcept C555293320 @default.
- W4387360641 hasConcept C62746215 @default.
- W4387360641 hasConcept C71924100 @default.
- W4387360641 hasConcept C90924648 @default.
- W4387360641 hasConceptScore W4387360641C126322002 @default.
- W4387360641 hasConceptScore W4387360641C134018914 @default.
- W4387360641 hasConceptScore W4387360641C2775967933 @default.
- W4387360641 hasConceptScore W4387360641C2776670229 @default.
- W4387360641 hasConceptScore W4387360641C2776919658 @default.
- W4387360641 hasConceptScore W4387360641C2777180221 @default.
- W4387360641 hasConceptScore W4387360641C2777482532 @default.
- W4387360641 hasConceptScore W4387360641C2778096610 @default.
- W4387360641 hasConceptScore W4387360641C2778110834 @default.
- W4387360641 hasConceptScore W4387360641C2778114629 @default.
- W4387360641 hasConceptScore W4387360641C2778163477 @default.
- W4387360641 hasConceptScore W4387360641C2778913445 @default.
- W4387360641 hasConceptScore W4387360641C2779091943 @default.
- W4387360641 hasConceptScore W4387360641C2780323712 @default.
- W4387360641 hasConceptScore W4387360641C2780745583 @default.
- W4387360641 hasConceptScore W4387360641C2910068830 @default.
- W4387360641 hasConceptScore W4387360641C555293320 @default.
- W4387360641 hasConceptScore W4387360641C62746215 @default.
- W4387360641 hasConceptScore W4387360641C71924100 @default.
- W4387360641 hasConceptScore W4387360641C90924648 @default.
- W4387360641 hasIssue "Supplement_1" @default.
- W4387360641 hasLocation W43873606411 @default.
- W4387360641 hasOpenAccess W4387360641 @default.
- W4387360641 hasPrimaryLocation W43873606411 @default.
- W4387360641 hasRelatedWork W2007723242 @default.
- W4387360641 hasRelatedWork W2018768201 @default.
- W4387360641 hasRelatedWork W2019363123 @default.
- W4387360641 hasRelatedWork W2036448246 @default.
- W4387360641 hasRelatedWork W2150524082 @default.
- W4387360641 hasRelatedWork W2323631355 @default.
- W4387360641 hasRelatedWork W2360031701 @default.
- W4387360641 hasRelatedWork W2376198676 @default.
- W4387360641 hasRelatedWork W2386858670 @default.
- W4387360641 hasRelatedWork W3084409504 @default.
- W4387360641 hasVolume "7" @default.
- W4387360641 isParatext "false" @default.
- W4387360641 isRetracted "false" @default.
- W4387360641 workType "article" @default.